A multi-stakeholder consensus published in the British Journal of Cancer proposes a practical roadmap to improve clinical trial execution in rare childhood central nervous system tumors. The authors argue the field has been limited by study systems that have not kept pace with scientific advances in these diseases. The roadmap is designed to support trials that are more practical, more inclusive, and better aligned with how small patient populations can be studied. It addresses structural barriers that have made it difficult to run adequately powered, timely studies across heterogeneous rare CNS tumor categories. For biotech and clinical researchers, the framework offers an operational guide that could reduce friction in trial design and recruitment, potentially enabling more consistent generation of evidence for emerging therapies. The publication also signals ongoing efforts by funders, clinicians, and researchers to coordinate rare-disease trial pathways rather than treating each program as a one-off.